Tanezumab for Chronic low Back Pain: A Long-Term, Randomized, Celecoxib-Controlled Japanese Phase III Safety Study

References

• Institutes for Health Metrics and Evaluation . Global burden of disease (GBD) compare. (2019). https://vizhub.healthdata.org/gbd-compare/
   Google Scholar
• Iizuka Y , IizukaH , MiedaTet al. Prevalence of chronic nonspecific low back pain and its associated factors among middle-aged and elderly people: an analysis based on data from a musculoskeletal examination in Japan. Asian Spine J11(6), 989–997 (2017).
   PubMed Web of Science ®Google Scholar
• Fujii T , MatsudairaK. Prevalence of low back pain and factors associated with chronic disabling back pain in Japan. Eur. Spine J.22(2), 432–438 (2013).
   PubMed Web of Science ®Google Scholar
• Kamada M , KitayuguchiJ , LeeIMet al. Relationship between physical activity and chronic musculoskeletal pain among community-dwelling Japanese adults. J. Epidemiol.24(6), 474–483 (2014).
   PubMed Web of Science ®Google Scholar
• Takahashi A , KitamuraK , WatanabeYet al. Epidemiological profiles of chronic low back and knee pain in middle-aged and elderly Japanese from the Murakami cohort. J. Pain Res.11, 3161–3169 (2018).
   PubMed Web of Science ®Google Scholar
• Montgomery W , SatoM , NagasakaY , VietriJ. The economic and humanistic costs of chronic lower back pain in Japan. Clinicoecon Outcomes Res9, 361–371 (2017).
   PubMed Web of Science ®Google Scholar
• Qaseem A , WiltTJ , McleanRM , ForcieaMA. Noninvasive treatments for acute, subacute, and chronic low back pain: a clinical practice guideline From the American College of Physicians. Ann. Intern. Med.166(7), 514–530 (2017).
   PubMed Web of Science ®Google Scholar
• Deyo RA , DworkinSF , AmtmannDet al. Report of the NIH Task Force on research standards for chronic low back pain. J. Pain15(6), 569–585 (2014).
   PubMed Web of Science ®Google Scholar
• Chou R , DeyoR , FriedlyJet al. Systemic pharmacologic therapies for low back pain: a systematic review for an American College of Physicians Clinical Practice Guideline. Ann. Intern. Med.166(7), 480–492 (2017).
   PubMed Web of Science ®Google Scholar
• The Committee for Clinical Practice Guidelines for Chronic Pain . Clinical practice guidelines for chronic pain. (2019). http://plaza.umin.ac.jp/~jaspain/pdf/consortium_20180913en.pdf
   Google Scholar
• Ng SC , ChanFK. NSAID-induced gastrointestinal and cardiovascular injury. Curr. Opin. Gastroenterol.26(6), 611–617 (2010).
   PubMed Web of Science ®Google Scholar
• Enthoven WT , RoelofsPD , DeyoRA , Van TulderMW , KoesBW. Non-steroidal anti-inflammatory drugs for chronic low back pain. Cochrane Database Syst. Rev.2(2), Cd012087 (2016).
   PubMedGoogle Scholar
• Barker PA , MantyhP , Arendt-NielsenL , ViktrupL , TiveL. Nerve growth factor signaling and its contribution to pain. J. Pain Res.13, 1223–1241 (2020).
   PubMed Web of Science ®Google Scholar
• Schmelz M , MantyhP , MalfaitAMet al. Nerve growth factor antibody for the treatment of osteoarthritis pain and chronic low-back pain: mechanism of action in the context of efficacy and safety. Pain160(10), 2210–2220 (2019).
   PubMed Web of Science ®Google Scholar
• Markman JD , Czerniecka-FoxxK , KhalsaPSet al. AAPT diagnostic criteria for chronic low back pain. J. Pain21(11–12), 1138–1148 (2020).
   PubMed Web of Science ®Google Scholar
• Sugiura A , OhtoriS , YamashitaMet al. Existence of nerve growth factor receptors, tyrosine kinase a and p75 neurotrophin receptors in intervertebral discs and on dorsal root ganglion neurons innervating intervertebral discs in rats. Spine (Phila Pa 1976)33(19), 2047–2051 (2008).
   PubMed Web of Science ®Google Scholar
• Taguchi T , HoheiselU , MenseS. Dorsal horn neurons having input from low back structures in rats. Pain138(1), 119–129 (2008).
   PubMed Web of Science ®Google Scholar
• Freemont AJ , PeacockTE , GoupilleP , HoylandJA , O’brienJ , JaysonMI. Nerve ingrowth into diseased intervertebral disc in chronic back pain. Lancet350(9072), 178–181 (1997).
   PubMed Web of Science ®Google Scholar
• Freemont AJ , WatkinsA , LeMaitre Cet al. Nerve growth factor expression and innervation of the painful intervertebral disc. J. Pathol.197(3), 286–292 (2002).
   PubMed Web of Science ®Google Scholar
• Markman JD , BolashRB , McalindonTEet al. Tanezumab for chronic low back pain: a randomized, double-blind, placebo- and active-controlled, Phase III study of efficacy and safety. Pain161(9), 2068–2078 (2020).
   PubMed Web of Science ®Google Scholar
• Katz N , BorensteinDG , BirbaraCet al. Efficacy and safety of tanezumab in the treatment of chronic low back pain. Pain152(10), 2248–2258 (2011).
   PubMed Web of Science ®Google Scholar
• Kivitz AJ , GimbelJS , BramsonCet al. Efficacy and safety of tanezumab versus naproxen in the treatment of chronic low back pain. Pain154(7), 1009–1021 (2013).
   PubMed Web of Science ®Google Scholar
• Schnitzer TJ , EastonR , PangSet al. Effect of Tanezumab on joint pain, physical function, and patient global assessment of osteoarthritis among patients with osteoarthritis of the hip or knee: a randomized clinical trial. JAMA322(1), 37–48 (2019).
   PubMed Web of Science ®Google Scholar
• Berenbaum F , BlancoFJ , GuermaziAet al. Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period. Ann. Rheum. Dis.79(6), 800–810 (2020).
   PubMed Web of Science ®Google Scholar
• Miller CG , GuermaziA , RoemerF. The current status of imaging in anti-NGF clinical trials. Osteoarthritis Cartilage23(Suppl. 1), S3–S7 (2015).
   PubMed Web of Science ®Google Scholar
• Tive L , BelloAE , RadinDet al. Pooled analysis of tanezumab efficacy and safety with subgroup analyses of phase III clinical trials in patients with osteoarthritis pain of the knee or hip. J. Pain Res.12, 975–995 (2019).
   PubMed Web of Science ®Google Scholar
• Celecoxib USPI (February 10). http://labeling.pfizer.com/showlabeling.aspx?id=793
   Google Scholar
• Hochberg MC . Serious joint-related adverse events in randomized controlled trials of anti-nerve growth factor monoclonal antibodies. Osteoarthritis Cartilage23(Suppl. 1), S18–S21 (2015).
   PubMed Web of Science ®Google Scholar
• Hochberg MC , TiveLA , AbramsonSBet al. When is osteonecrosis not osteonecrosis?: adjudication of reported serious adverse joint events in the Tanezumab Clinical Development Program. Arthritis Rheumatol68(2), 382–391 (2016).
   PubMed Web of Science ®Google Scholar
• Ashworth J , GreenDJ , DunnKM , JordanKP. Opioid use among low back pain patients in primary care: is opioid prescription associated with disability at 6-month follow-up?Pain154(7), 1038–1044 (2013).
   PubMed Web of Science ®Google Scholar